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Abstract
In this paper, we describe a nonlinear threshold chemistry based on enzymatic inhibition and 
demonstrate how it can be coupled with microfluidics to convert a chemical concentration (analog 
input) into patterns of ON or OFF reaction outcomes (chemical digital readout). Quantification of 
small changes in concentration is needed in a number of assays, such as that for cystatin C, where 
a 1.5-fold increase in concentration may indicate the presence of acute kidney injury or the 
progression of chronic kidney disease. We developed an analog-to-digital chemical signal 
conversion that gives visual readout and applied it to an assay for cystatin C as a model target. The 
threshold chemistry is based on enzymatic inhibition and gives sharper responses with tighter 
inhibition. The chemistry described here uses acetylcholinesterase (AChE) and produces an 
unambiguous color change when the input is above a pre-determined threshold concentration. An 
input gives a pattern of ON/OFF responses when subjected to a monotonic sequence of threshold 
concentrations, revealing the input concentration at the point of transition from OFF to ON 
outcomes. We demonstrated that this threshold chemistry can detect a 1.30–fold increase in 
concentration at 22 °C, and that it is robust to experimental fluctuations: it provided the same 
output despite changes in temperature (22–34 °C) and readout time (10-fold range). We applied 
this threshold chemistry to diagnostics by coupling it with a traditional sandwich immunoassay for 
serum cystatin C. Because one quantitative measurement comprises several assays, each with its 
own threshold concentration, we used a microfluidic SlipChip device to process 12 assays in 
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parallel, detecting a 1.5-fold increase (0.64 mg/L (49 nM) to 0.96 mg/L (74 nM)) of cystatin C in 
serum. We also demonstrated applicability to analysis of patient serum samples and the ability to 
image results using a cell phone camera. This work indicates that combining developments in 
nonlinear chemistries with microfluidics may lead to the development of user-friendly diagnostic 
assays with simple readouts.
INTRODUCTION
This paper describes the conversion of a chemical analog input (concentration) via chemical 
reactions into a digital output, which is represented by a pattern of ON/OFF binary digits 
(bits) (Figure 1). To achieve such responses, we implemented a threshold chemistry that 
produces a color change above a predetermined threshold concentration of input. Visual 
inspection of the pattern of bits with the naked eye or with a simple imaging device such as 
a cell phone indicates whether the input concentration is above or below the threshold 
concentration. In this paper, we report theory, experiments, and evaluation of this chemistry 
in the context of a realistic problem: quantifying small changes in the concentration of 
serum cystatin C (which inversely correlates with kidney performance).1 We are not 
presenting a clinical device that is ready for market, but we have chosen to assess the 
threshold chemistry within a realistic context, with a clinically relevant analyte and a 
clinically relevant change in concentration.
Simple readerless qualitative assays, such as pregnancy test strips, work well with various 
analytes and are widely utilized. Qualitative assays have two advantages: their simple 
readout eliminates the need for a machine (reader) to interpret the results, and they are 
usually robust to changes in temperature and assay time. Quantitative assays, however, 
typically rely on kinetic measurements for quantification, and therefore require careful 
control of temperature and assay time to accurately detect small changes in concentration. 
Simple quantitative assays2,3 can be readerless and can detect changes in concentration over 
a large range, but the change in readout is apparent only if those changes are one order of 
magnitude or more. With traditional analog readout, such as in an enzyme-linked 
immunoassay, the amount of output chemical is approximately proportional to input analyte 
concentration, and smaller changes in output lead to subtle changes in color that are hard to 
detect accurately with the naked eye. To quantify smaller changes, readers must be used to 
detect absorbance, fluorescence, and voltage.4-6
Quantification of small increases in concentration is needed for a number of assays. For 
example, a 1.5-fold increase in serum cystatin C concentration soon after a traumatic 
incident may indicate acute kidney injury (AKI),7 which carries increased morbidity and 
mortality. In chronic kidney disease (CKD), increases in cystatin C as small as 1.5-fold 
(from < 0.7 mg/L to > 0.9 mg/L) may indicate the progression from normal kidney function 
to stage 3 CKD, which entails complications such as anemia, bone-mineral disease, and life-
threatening electrolyte abnormalities (Table S1 in Supporting Information1,8). We therefore 
chose an assay for cystatin C as a model system.
Here, we asked whether exploiting chemical nonlinearities can produce chemistry that gives 
robust, readerless quantification of small changes of concentrations despite changes in 
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temperature or time. We tested the idea of “digitizing” the analog chemical signal such that 
the concentration is presented as a series of ON/OFF bits. At the single-molecule level, such 
analog-to-digital chemical conversion can be performed with digital PCR9,10 and digital 
immunoassays11 by using microfluidic devices to split a sample into small compartments 
containing individual molecules. This digital approach can provide quantitative information 
despite changes in temperature,12 but typically requires a reader. Instead of physically 
compartmentalizing the individual molecules of the sample, we wished to explore the 
potential to chemically digitize the analog signal (i.e., concentration) itself. We implemented 
the analog-to-digital conversion of the input concentration by using threshold chemistry, in 
which a reaction gives an OFF response if the input concentration of the signal is lower than 
the threshold concentration and gives an ON response—a prominent color change—
otherwise (Figure 1A). In this framework, each reaction comprises one “bit.” Multiple bits 
with different threshold concentrations can be processed in parallel. Arranged in increasing 
order of threshold concentration, these bits combine to give a distinct point of transition 
from OFF bits to ON bits, enabling simple visual readout (Figure 1B). Different input 
concentrations cause the transition to occur at different locations along the series of bits 
(Figure 1C).
In principle, any threshold chemistry could be used to implement this approach. Thresholds 
are common in chemical reaction networks in Nature,13-16 and several synthetic threshold 
chemistries have been developed.17-19 In practice, we set four requirements for the threshold 
chemistry to be used for analog-to-digital conversion: i) it must be able to detect increases in 
concentration that are small enough to match the sensitivity requirements of the assay; ii) it 
must be tunable to different threshold concentrations; iii) it must provide visual readout 
detectable by the naked eye; and iv) it must be adaptable for different assays. Many 
established threshold chemistries were not sharp enough for this purpose: they are capable of 
detecting 2- to 10-fold increases in concentration,17-19 while a useful assay for cystatin C, 
for example, requires detection of 1.5-fold or smaller increases. A threshold chemistry based 
on quenching the product of a 1 : 1 conversion (1 product molecule from 1 input 
molecule)20 can work only at concentrations high enough to enable the product to be seen 
without amplification. Natural threshold chemistries13,14 and those inspired by nature15,16 
can be much sharper but require complex systems of enzymes that are not easily adapted to 
assays. An elegant system has been developed to use the metabolic “branch point effect” to 
generate digital outputs that are results of inputs of mM glucose concentration and are 
detected by an electrical reader.21 However, we wished to develop a general system that is 
compatible with current immunoassays, is sensitive to concentrations below μM, and gives 
visual readout. In principle, the metabolic “branch point effect” system could be engineered 
further to perform analog-to-digital chemical conversion, but we found a solution of a 
different type that can resolve small steps (1.22-fold in theory and 1.30-fold in experiments) 
at nM concentrations and has the potential to be adapted to other assays that give the biotin 
group as the reporter.
RESULTS AND DISCUSSION
The threshold chemistry evaluated here is based on enzymatic inhibition: the enzyme is 
incubated with the competitive inhibitor first, and then, it is allowed to react with the 
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substrate. The concentration of available active enzyme (output) increases dramatically 
when the total concentration of enzyme (input) changes from just below the concentration of 
the inhibitor to just above it. This increase in output is larger when the inhibitor binds more 
tightly to the enzyme.23 We first analytically specify the requirements for the threshold 
chemistry to be functional by considering the binding between the enzyme and the inhibitor. 
We consider only this step because it is where the threshold is set up, and we do not explore 
upstream steps (analyte and enzyme) or downstream steps (enzymatic reaction and other 
reactions for readout). Suppose we have two inputs (i.e., two enzyme concentrations) that 
need to be distinguished from one another. The inhibitor concentration, which is the 
threshold concentration (thresh_conc), is set to be the average value of the inputs. We define 
the dimensionless parameters α (where 0 < α < 1) and γ (where 0 < γ < 1) to describe the 
resolution and sharpness of the threshold chemistry, such that the two inputs, (1 − α)* 
thresh_conc and (1 + α) * thresh_conc, give relative outputs of (1 − γ) and 1, respectively 
(Figure 2B). The resolution (ratio of the two inputs that gives distinguishable outputs) is (1 + 
α)/(1 + α) and the corresponding ratio of outputs is 1/(1 − γ)
The threshold chemistry is considered to be sharp when the ratio of outputs is large even 
with a small ratio of inputs. The parameters α and γ (Equation 1 and Figure 2B) are dictated 
by the requirements of the assay. If a small increase in concentration needs to be detected, 
then α must be small. If a large difference in output needs to be detected, for instance, to 
enable easy visual readout, then the ratio of outputs and γ need to be large.
(1)
With a certain required resolution (1 + α)/(1 + α), the minimum threshold concentration 
(min_thresh_conc) that can give a ratio of outputs ≥ 1/(1 − γ) is given by Equation 2 (see the 
Supporting Information for derivation), where Ki is the dissociation constant of the enzyme/
inhibitor complex. The model used to obtain this result consists of enzyme/inhibitor 
equilibrium followed by Michaelis-Menten kinetics.
(2)
According to Equation 2, one would like to choose as small a ki as possible, so that when the 
parameters α and γ are predetermined, the threshold chemistry has as large a working range 
of concentrations as possible (lowest min_thresh_conc), or so that when the 
min_thresh_conc is predetermined, one has as sharp a threshold as possible (large γ with 
small α).
To evaluate this idea, we chose acetylcholinesterase (AChE) as the enzyme (Figure 2A). We 
used a potent inhibitor, syn-(S)-TZ2PIQ-A5, with Ki= 33 fM.22 when the concentration of 
the enzyme is higher than that of the inhibitor, it hydrolyzes acetylthiocholine to give 
thiocholine, which reduces the purple suspension of I3−/starch complex to give a clear 
mixture, enabling threshold responses (Figures 1, 2). To achieve a resolution of 1.22 = (1 + 
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0.1)/(1 − 0.1) (with α = 0.1) and a ratio of outputs of 10 = 1/(1 − 0.9) (with γ = 0.9), we have 
min_thresh_conc = 26.4 pM , and min_thresh_conc/Ki = 801 (Equation 2). To verify those 
predictions, we fixed the resolution (by maintaining α = 0.1), varied thresh_conc/Ki (by 
changing thresh_conc or Ki) and calculated γ in each case (by using both rate laws and 
simulation with ordinary differential equations) (Figure 2C). Only when thresh_conc/Ki ≥ 
min_thresh_conc/Ki = 801 did we find γ ≥ 0.9, satisfying the requirement for producing a 
large distinction in outputs, suitable for visual readout. Note that these calculations assume 
idealized kinetics, ignoring a number of potential confounding factors present in 
experiments (e.g., changes of enzymatic activity in the presence of proteins present in 
realistic samples, or competition between the inhibitor and the substrate used for readout of 
enzyme activity).
We experimentally detected 1.30-fold increases at nM AChE concentrations with visual 
readout (Figure 2D). The concentration of input, avidin-conjugated AChE (avidin-AChE), 
increased by 1.30-fold going across each row of wells on a 96-well plate, while the threshold 
concentration (set by concentration of the inhibitor) increased 1.30-fold going down each 
column. In each well, avidin-AChE and the inhibitor were incubated before the addition of 
the substrate mixture (acetylthiocholine/I3-/starch). The reactions produced ON (clear) or 
OFF (dark) responses, visible by the naked eye, depending on whether the enzyme 
concentration was larger or smaller than the inhibitor concentration.
Furthermore, we found that this threshold chemistry is robust to changes in temperature and 
readout time (Figure 3 and 4). We used a plate reader to control the temperature and 
measure absorbance from well-plate reactions of acetylcholinesterase with the chromogenic 
substrate 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) (absorbance ∝ [product]).24 This 
experiment was designed to follow the principle of the analog-to-digital conversion (Figure 
1B): subjecting one concentration of input (enzyme concentration) to multiple thresholds 
(set by inhibitor concentrations). To test thresholds at high (1.3-fold) resolution, at each 
temperature, six reactions were set up with the inhibitor concentration following a 1.3× 
dilution series from 13 to 46 nM. Reactions with inhibitor concentrations that were lower 
than the enzyme concentration gave ON results (13, 16, 21 nM), while the rest gave OFF 
results (27, 36, 46 nM). This threshold was robust: the contrast between ON and OFF 
reactions was consistent over a range of readout times (3–30 min), a range of temperatures 
(22–34 °C), and three repeats (Figure 3A). This result, predicted by equation 2, was 
somewhat surprising because this equation does not capture a number of complications, 
including the temperature dependence of enzyme-substrate and enzyme-inhibitor binding, 
and also the competition between inhibitor present at a low concentration and readout 
substrate present at a high concentration. We also found that when the enzyme and the 
inhibitor were diluted 10 times, the threshold chemistry yielded narrower working ranges in 
temperature and readout (25 °C/3–10 min; 28-34 °C/3-30 min) (Figure 3B). We observed 
agreement between results from robustness experiments and the model (Figure 4). We used 
28 °C because this falls in the middle of the range of temperatures that we tested 
experimentally. The plot of the model in Figure 4 was generated using analytical 
calculations of the enzyme/inhibitor equilibrium (Equation S5) before the enzymatic 
reaction, followed by use of the Michaelis-Menten model to simulate the enzymatic reaction 
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(with inhibition) via numerically solving ordinary differential equations. The concentrations 
used in the model match those from the robustness experiments (Figure 3A), and the rate 
constants were obtained from previously published work.22,25
To test this chemistry in the assay for cystatin C, we used a bead-based sandwich assay, in 
which the analyte cystatin C molecule was bound by two different antibodies (Figure 5A). 
The capture antibody was conjugated to magnetic beads, while the detection antibody was 
conjugated to biotin, which can bind to avidin-AChE. The amount of AChE immobilized on 
the beads should therefore correlate to the amount of cystatin C. The magnetic beads 
allowed for washing and physical transfer of the whole complex from well to well 
throughout the multi-step process.
This analog-to-digital conversion replaces a single analog experiment with multiple 
ON/OFF digital experiments, and uses an approach that enables one to perform multiple 
experiments in parallel easily while minimizing consumption of samples and reagents. Such 
multiplexing and miniaturization are enabled by microfluidics, and we used a SlipChip26 
microfluidic device to evaluate the chemistry and the feasibility of the overall approach. The 
SlipChip we used was composed of two plates that face one another, each having recessed 
features (wells, ducts, etc.) to contain aqueous reagents. Complex manipulations of fluids 
can be programmed into a SlipChip as a pattern of these features. The user can then execute 
the program by moving these features relative to one another by slipping the plates. This 
enables multistep processing for a number of applications.12,26,27
We designed the SlipChip (Figure 5B, C) based on previously published designs for 
performing immunoassays,27 with an extra step of inhibition, a modified washing 
mechanism (Figure 5C), different surface coating (fluorinated ethylene propylene), and 
different loading and assembly protocols. Each of the 12 columns of wells on the chip 
performs one assay with a certain predetermined threshold concentration. As the top plate 
moves relative to the bottom plate, the steps of the assay are performed sequentially in each 
column (Figure 5D), and all of the columns are processed at the same time so that the assays 
run in parallel.
To test whether this combination of threshold chemistry (Figure 2) and microfluidics (Figure 
5) could enable detection of a 1.5-fold increase in the concentration of cystatin C in serum, 
we set up a device with 1.5-fold steps of increasing inhibitor concentration going from left 
to right (Figure 6A). In these experiments, we used purified cystatin C dissolved in cystatin 
C-free serum to avoid confounding the experiments by potential variability of cystatin C 
concentration in serum of patients. In each column, the output was OFF (dark) if the input 
(concentration of cystatin C) was below the threshold concentration, and the output turned 
ON (clear) otherwise. The transition position was defined as the point in the bottom row at 
which a clear-to-dark step was observed. A cystatin C concentration of 0.64 mg/L, which is 
in the range of normal kidney function, transitioned between columns 8 and 9, producing 4 
wells with OFF outputs. The concentration of 0.96 mg/L, which corresponds to stage 3 
chronic kidney disease, transitioned between columns 10 and 11, producing 2 wells with 
OFF outputs (Figure 6B). Experimental details are described in Supporting Information.
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We performed two additional sets (4 chips) of experiments, which also showed a difference 
in the position of the transition between these two concentrations. All three sets of 
experiments gave aggregated results of (3, 4, 5) wells with OFF outputs for 0.64 mg/L and 
(2, 2, 2) wells with OFF outputs for 0.96 mg/L. Thus, an increase of 1.5-fold (0.64 to 0.96 
mg/L) resulted in a statistically significant difference in outputs (1-tailed p-value of 0.0129) 
for this combination of threshold chemistry and microfluidics.
Next, we tested whether we could systematically adjust the threshold concentrations over a 
large dynamic range, and whether this approach would still perform adequately when used 
with patient samples. The patient samples were collected and characterized for purposes 
other than this project (for a prospective observational study investigating novel biomarkers 
of renal tubular injury following adult cardiac surgery),28,29 archived, and de-identified. 
Once collected, the samples were centrifuged and the supernatant was kept and immediately 
frozen at −80 °C. The samples that we used were known to have high (3.29 mg/L) and low 
(0.75 mg/L) cystatin C values. We chose to test samples from patients with variable renal 
function in order to gain values across the spectrum of disease and across the range of the 
assay. For controls, we measured concentrations independently using a commercially 
available ELISA kit with the platform of microtiter plates. With the same chip design, the 
inhibitor concentrations within rows were modified to detect bigger steps (2-fold) in 
concentration, with a larger overall range of detection (0.64-5.12 mg/L) and correspondingly 
coarser resolution. The 12 columns on the chip enabled us to set up some of the thresholds 
in duplicate. This was most useful at low concentrations (and correspondingly, closer 
transitions), where we observed some noise (out-of-order transitions) for the 1.39 mg/L 
concentration. Overall, we observed good agreement between ON/OFF transitions for the 
two samples from patients and those for four standard solutions of known concentration 
(solution of purified cystatin C dissolved in cystatin C-free serum) (Figure 7A). The contrast 
of the visual readout was strong enough to be recorded with the camera of a cell phone 
(iPhone 4) (Figure 7B). We emphasize that there is a trade-off between the resolution, 
dynamic range, and the number of experiments (and therefore the complexity of the 
microfluidic device) required to implement this analog-to-digital conversion.
We now discuss the features of this approach, its potential shortcomings, and the remaining 
challenges to its implementation, as well as its implications for diagnostic testing using 
kidney injury as an example. In terms of chemistry, the use of tight AChE-inhibitor binding 
combined with iodine-starch based readout is attractive because it can be implemented for 
any sandwich immunoassay, as long as the detection antibody can be conjugated to biotin. 
The limits of performance of such threshold chemistry would be defined by Equation 2. 
When the input concentration is sufficiently larger or smaller than the threshold 
concentration, variation in input concentration does not affect the reaction time, because the 
reaction time is either very fast or very slow, respectively. However, the sensitive range 
around the threshold is one disadvantage of this chemistry (and any other threshold 
chemistry). We use the parameter α (Equation 1 and Figure 2B) to specify how far away 
from the threshold concentration the input concentration needs to be for robust performance. 
Input concentrations sufficiently larger than the threshold concentration (Io (1 + α) < input, 
where Io is the threshold concentration) would make the reactions finish much faster than 
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those from input concentrations slightly smaller than the threshold concentration (input < Io 
(1 − α) (Figure 2). The reactions from the former cases would all finish before the reactions 
from the latter case have hardly started, and the readout time would not depend on 
concentration in those cases. However, when the input concentration is minimally below or 
above the threshold concentration (o (1 − α) < input < Io (1 + α)), the chemistry may result 
in intermediate outputs, which may not be easily distinguished from those sufficiently 
smaller or larger than the threshold. Quantitatively, when the input increases from Io (1 − α) 
to Io (1 + α), the output increases 1 / (1 − γ) times (10 times when γ = 0.9). In general, any 
threshold chemistry, by definition, has a sensitive range around the threshold and gives 
robust output outside the sensitive range. In particular, this threshold chemistry would also 
give slower reactions (regardless of the threshold) when the absolute concentrations are 
lower. Some improvement can be achieved by increasing the enzymatic turnover rate or 
change in absorbance per turnover. An even better approach would be to develop additional 
nonlinear amplification chemistries that would give even higher resolution and faster 
readout time. For example, due to the tight and specific binding in DNA and RNA 
hybridization, we see significant potential in nucleic acid amplification strategies based on 
autocatalytic enzymatic (e.g., polymerase chain reaction and various flavors of isothermal 
chemistries12,30,31) amplification or enzyme-free amplification strategies based on DNA-
circuits and DNA computation.32-35 Such approaches, combined with microfluidics, could 
extend analog-to-digital conversion to quantification of nucleic acids. Furthermore, aptamers 
and related nucleic acid-based reagents36 already used for detection of proteins and small 
molecules may enable combining threshold approaches and amplification of nucleic acids. 
This could open the door for the detection of a wide range of molecules beyond nucleic 
acids. Finally, we see opportunities for exquisite molecular control provided by an exciting 
array of chemical amplification approaches using autocatalysts, such as diarylketone,37 
piperidine,38 fluoride,39 hydrogen peroxide, and glucose.40 These amplification chemistries, 
when coupled with controls to provide threshold behavior, chemistries to correlate with 
target analytes, and appropriate devices, will provide quantification techniques for a wide 
range of analytes and uses.
Here, we have used microfabricated devices produced in a research laboratory and operated 
by a trained user. For diagnostic use, a mass-produced device would be required, with on-
board reagent storage and stabilization. For measuring an analyte with only a few discrete 
clinically relevant cut-offs, such as cystatin C, a device that performs approximately a dozen 
parallel assays is sufficient. However, larger numbers of assays would be needed for 
measurements that require higher dynamic range or finer resolution than those presented 
here, to generate redundant assays, and to implement on-chip controls and calibration.
We have not optimized the speed of the assay (each chip assay took about 4.5 hours, with 
the major time-consuming steps being analyte binding and the readout reaction). Now that 
we have demonstrated that the analog-to-digital conversion chemistry can be used in the 
context of a realistic assay, such optimization of timing would be appropriate for subsequent 
work.
While visual readout and immediate interpretation are attractive for designs with only a few 
assays, the ability to read the assay with a cell phone (Figure 7B) is appealing for several 
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reasons: i) interpreting results of controls and calibrations and inferring the validity of the 
assay; ii) performing statistical interpretation of the data to provide confidence intervals for 
assay results; and iii) transmitting the data to physicians and archiving data in electronic 
medical record (EMR) databases. For example, acute kidney injury is detectable by 
measuring cystatin C levels in a range compatible with this approach. Diagnosing AKI 
under limited-resource settings may be needed in events of trauma (injuries of the kidney or 
injuries that lead to sudden, serious blood loss, blockage of the urinary tract, or poisoning) if 
laboratory-based medical testing is impractical or unavailable. Such situations may arise in 
the event of accidents in remote areas or injuries after natural disasters such as earthquakes 
that damage infrastructure (where crush injuries and the resultant rhabdomyolysis result in 
kidney injury). Furthermore, chronic kidney disease offers another reason to measure 
cystatin C under limited-resource settings, such as in developing countries. In the United 
States, as well, awareness of chronic kidney disease remains low among the estimated 20 
million people afflicted (7.8 % awareness for individuals with stage 3 disease41), even 
though cystatin C immunoassays are available in hospitals. In both acute kidney injury and 
chronic kidney disease, identifying small increases in the concentration of cystatin C (1.5-
fold or smaller) is crucial for accurate diagnosis. The availability of an assay that can 
quantify these small increases would enable timely detection of acute kidney injury and 
encourage screening to increase awareness of chronic kidney disease, facilitating care. 
Robustness of digitized assays to temperature and reaction time (Figure 3) may aid 
implementation of such assays in limited-resource settings, because it could enable simple 
devices for quantitative measurements without requiring precise control of temperature or 
timing of the measurement.
CONCLUSIONS
We draw five conclusions from this work: i) Analog-to-digital signal conversion can be 
implemented using threshold chemistry (as discussed above, the analog-to-digital 
conversion described in this paper is distinct from “digital” single-molecule 
measurements9-11); ii) This threshold chemistry shows robustness to variations in 
temperature and readout time; iii) The threshold chemistry can be implemented within the 
realistic context of a cystatin C assay: combined with a microfluidic device, it detected a 
1.5-fold increase in the concentration of cystatin C in serum at nM concentrations, and the 
assay performed properly with clinical samples; iv) An advantage of this method is that it 
provides quantitative information interpretable by the naked eye or a cell-phone camera, 
without requiring quantitative instrumentation; v) A disadvantage of analog-to-digital signal 
conversion is that one assay is replaced with multiple assays (the number of assays depends 
on the resolution and the dynamic range desired). Advances in microfluidics could enable 
parallel manipulations, reduce the amount of sample required, and make digital-to-analog 
conversion feasible with no extra reagent cost or user intervention. Clinically validated and 
field-usable readerless quantitative assays suitable for providing medical care under limited-
resource settings, while not a goal of this paper, would be enabled by additional 
developments in automated user-friendly microfluidics and in threshold chemistries.
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Illustration of analog-to-digital conversion. A) A depiction of ON/OFF bits. If the input 
concentration is higher than the threshold concentration, the threshold chemistry gives an 
ON readout, shown as the color change from purple to white. If the input concentration is 
lower than the threshold concentration, the color remains purple, or OFF. B) An illustration 
of a series of ON/OFF bits. An input, when subjected to a series of increasing threshold 
concentrations, gives a series of ON/OFF responses, with the point of transition (red) 
between these ON and OFF states depending on the input concentration. C) An illustration 
of analog readout versus digital readout. An analog readout gives a gradient change in color 
intensity depending on input concentration (blue lettering). A digital readout comprises a 
series of bits; each bit is either clear (ON) or intensely colored (OFF), and the series of bits 
changes as the input concentration changes.
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Threshold chemistry achieved by competitive inhibition. A) A schematic drawing of the 
threshold chemistry and detection reactions. When the concentration of the enzyme 
acetylcholinesterase (AChE) exceeds that of the inhibitor (syn-(S)-TZ2PIQ-A522), the 
enzyme hydrolyzes acetylthiocholine to give thiocholine, which reduces the purple 
suspension of I3−/starch complex and results in a clear mixture. B) Graphical definition of 
the parameters α and γ (Equation 1). C) A plot comparing γ values calculated from different 
thresh_conc/Ki via analytical calculations (ana.) and numerical simulations (sim.) with γ = 
0.9 at min_thresh_conc/Ki = 801 as predicted by Equation 2. D) A photograph showing 
detection of 1.30-fold increases in enzyme concentration with multiple threshold 
concentrations and visual readout in a 96-well plate. Details of image handling can be found 
in the Supporting Information.
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Robustness of threshold chemistry at different temperatures and readout times. A) False-
color maps depict 90 time traces of absorbance from 90 threshold reactions of 
acetylcholinesterase with a chromogenic substrate (see text for details) as the inhibitor 
concentrations were changed in a series of 1.3× dilutions (13, 16, 21, 27, 36, and 46 nM) 
across a 12-degree range of temperatures (22 °C, 25 °C, 28 °C, 31 °C, and 34 °C). B) False-
color maps depict 90 time traces of absorbance from 90 threshold reactions of 
acetylcholinesterase with a chromogenic substrate as the inhibitor concentrations were 
arranged in a series of 1.3× dilutions (1.3, 1.6, 2.1, 2.7, 3.6, and 4.6 nM; 10 times less 
[enzyme] and [inhibitor] compared to A) across a 12-degree range of temperatures. 
Experiment repeats are arranged in rows. Note that in this figure, higher absorbance (dark) is 
equivalent to higher enzymatic activity, which is opposite from the visual readout system 
used in other experiments.
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Comaparison of experimental results from robustness experiments and the model. The 
experimental results are the average of 3 repeats of the results shown in Figure 3A, at 3 
minutes and 28 °C. The plot of the model was generated using analytical calculations 
(Equation S5) before the enzymatic reaction and the Michaelis-Menten model to simulate 
the enzymatic reaction (with inhibition). Concentrations used in the model match those of 
the robustness experiments (Figure 3A).
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Illustrations of the immunoassay and SlipChip design. A) A drawing of the complex used in 
the magnetic bead-based immunoassay for cystatin C. B) A drawing of the overall SlipChip 
design. The chip has a top plate (black lines) and bottom plate (blue lines) that face each 
other. Each of the 12 columns is designed to perform an assay at a different threshold 
concentration, for a total of up to 12 threshold concentrations (or fewer, if duplicate assays 
are desired). Reagents are pre-loaded into the chip in rows into the layer shown in blue 
before the sample is introduced into the inlet. To perform each step of the assay, the top 
plate is slipped according to the “slip” arrow (solid black arrow), performing the assay on all 
12 columns in parallel. The green box indicates the column shown in D. C) Schematic of the 
washing mechanism, based on dragging magnetic beads through a channel containing 
washing solution (side view). When the top plate is slipped relative to the bottom plate, 
beads are moved to the beginning of the channel containing washing solution. A magnet is 
used to move the beads to the other end of the channel, and then, to another well on the top 
plate. The plate is then slipped once more to separate the beads and the channel. D) A time 
series illustrating the assay. Only one of the 12 columns is shown (11 times), illustrating the 
8 steps of the assay. The movement of the plates of the SlipChip (7 slips total) is shown. The 
blue (bottom) plate is stationary, and the top (black) plate moves along the direction of the 
arrow shown in B. The movement of magnetic beads (3 transfers) is shown with red dashed 
arrows.
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Assays designed to detect a 1.5-fold increase in cystatin C (0.64–0.96 mg/L), when a patient 
may progress from normal kidney function to acute kidney injury (AKI) or stage 3 chronic 
kidney disease (CKD). A) Schematic showing the arrangement of threshold concentrations 
on the device. The inhibitor droplets were loaded such that concentrations increased from 
left to right (0, 5.3, 7.9, 12, 18, 27, and 40 nM; identical colors indicate identical 
concentrations). B) Photographs showing ON-to-OFF transition for solutions of 0.64 mg/L 
(top) and 0.96 mg/L (bottom) cystatin C spiked into cystatin C-free serum. Scale bar: 2 mm. 
Images were taken with a consumer digital camera; details of image handling are included in 
the Supporting Information.
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Results from standard solutions and clinical serum samples over a wide dynamic range. A) 
Photographs of results, with each row corresponding to one assay (one SlipChip device). B) 
Photograph of the result of the 3.29 mg/L patient sample recorded with an iPhone 4 camera. 
Only the first 8 columns of the device described in Figure 5 are shown in Figure 7. The 
sequence of inhibitor concentrations was set up as in Figure 6A, but with larger steps in 
concentration (0, 9.4, 19, 38, 75, 150, and 300 nM). Columns 3–4, 5–6, 7–8, 9–10, and 11–
12 were set up as duplicates such that each pair contained the same inhibitor concentration. 
Scale bar: 2 mm. Details of image handling are included in the Supporting Information.
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